Biodel Announces Clinical and Corporate Updates DANBURY,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Biodel Announces Clinical and Corporate Updates

DANBURY, CT --(Marketwired - November 03, 2015) - Biodel Inc. ( NASDAQ : BIOD ) today announced the initiation of Study 3-157, a Phase 2a clinical trial to evaluate patient-friendly BIOD-531-based regimens against a state-of-the-art basal-bolus insulin regimen and in combination with a GLP-1 analog. Separately, following the completion of an operational review of the company, Biodel plans to focus on later stage clinical development programs and restructure research, quality assurance/quality control (QA/QC) and facilities activities to save approximately $2 million annually.

The Phase 2a Study 3-157 is designed to evaluate glucose control achieved with BIOD-531, Biodel's proprietary biphasic insulin formulation characterized by an ultra-rapid-acting onset and basal duration of action, compared to a state of the art "basal-bolus" regimen in patients with type 2 diabetes. The clinical trial will test the hypothesis that two or three doses of BIOD-531 alone can achieve equivalent glucose control to a commonly used intensive insulin regimen in which two different insulins are injected a total of four times per day. In addition, Study 3-157 will evaluate the clinical efficacy of co-treatment with Victoza®, a leading GLP-1 analog. Pre-clinical studies indicate that BIOD-531 can be stably co-formulated with liraglutide, the active pharmaceutical ingredient in Victoza®.

The primary endpoint for Study 3-157 is mean glucose concentration over a 24 hour period. On separate days, 14 subjects with type 2 diabetes will receive the following four treatments along with standardized meals in a randomized treatment sequence:

  • BIOD-531 with breakfast and dinner,
  • BIOD-531 with breakfast, lunch and dinner,
  • Insulin lispro (Humalog®) with breakfast, lunch and dinner plus insulin glargine (Lantus®) ("basal-bolus"), and
  • Liraglutide (Victoza®) in addition to BIOD-531 given with breakfast and dinner.

Dr. Errol De Souza, President and Chief Executive Officer of Biodel, stated: "The unique ultra-rapid-acting pharmacokinetic profile of BIOD-531, which is faster than marketed prandial insulins such as Humalog® while providing basal coverage in a single injection, may allow us to effectively compete in the large basal-bolus insulin market by reducing the injection burden and achieving glucose control at least as effective as that with separate basal and prandial insulins in patients with type 2 diabetes. Furthermore, the potential combination of BIOD-531 with a GLP-1 analog such as liraglutide could further expand the emerging basal insulin/GLP-1 combination market by providing additional superior prandial coverage. We look forward to reporting the topline data from Study 3-157 towards the end of the first calendar quarter of 2016."

In order to reduce infrastructure costs and improve efficiency of research and QA/QC-related activities, Biodel will reduce its workforce by 10 employees, or approximately 30%, which Biodel estimates will reduce annualized personnel expenses by approximately $2 million. One-time severance payments are expected to be approximately $0.3 million. The company will continue to pursue other cost controlling practices to further reduce its operating expenses.

Gary Gemignani, Chief Financial Officer of Biodel, stated: "We believe that these personnel changes will more closely align our ongoing efforts towards supporting our later-stage clinical programs, while extending our cash runway."

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. Biodel's product candidates are developed by applying proprietary technologies to existing drugs in order to improve their therapeutic profiles. More information about Biodel is available at www.biodel.com .

Safe-Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements about future activities related to the clinical development plans for Biodel's product candidates, potential timing, design and outcomes of clinical trials and Biodel's ability to develop and commercialize its product candidates. Forward-looking statements represent Biodel's management's judgment regarding future events. All statements, other than statements of historical facts, including statements regarding Biodel's strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Biodel's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, the progress, timing or success of Biodel's research and development and clinical programs for Biodel's product candidates; Biodel's ability to conduct the development work necessary to finalize the formulation and design of Biodel's auto-reconstitution glucagon rescue product candidate, as well as the preclinical studies, clinical trials and manufacturing activities necessary to support the filing of a new drug application, or NDA, to the U.S. Food and Drug Administration, or FDA, for that product candidate; Biodel's ability to engage a strategic partner in the further development of Biodel's prandial ultra-rapid-acting insulin formulations, including BIOD-531, which uses regular human insulin, or RHI, as the active pharmaceutical ingredient, and Biodel's insulin analog-based formulations; the success of Biodel's formulation development work to improve the stability of Biodel's newer ultra-rapid-acting insulin analog-based formulations while maintaining the pharmacokinetic and injection site toleration characteristics associated with earlier formulations; the results of Biodel's real-time stability programs for Biodel's RHI-, insulin analog- and glucagon-based product candidates, including the reproducibility of earlier, smaller scale, stability studies and Biodel's ability to accurately project long term stability on the basis of accelerated testing; Biodel's ability to accurately anticipate technical challenges that the company may face in the development of Biodel's ultra-rapid-acting RHI- and insulin analog-based product candidates or Biodel's glucagon rescue product candidates; Biodel's ability to secure approval by the FDA for Biodel's product candidates under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act; Biodel's ability to enter into collaboration arrangements for the commercialization of Biodel's product candidates and the success or failure of any such collaborations into which the company enters, or Biodel's ability to commercialize its product candidates on its own; Biodel's ability to enforce Biodel's patents for Biodel's product candidates and Biodel's ability to secure additional patents for Biodel's product candidates; and other factors identified in our most recent annual report on Form 10-K for the fiscal year ended September 30, 2014 and other subsequent filings with the Securities and Exchange Commission. The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.

BIOD-G

CONTACT: Clayton Robertson The Trout Group +1 (646) 378 2964

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 121

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 173

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 210

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 126

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 123

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 175

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 95

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 157

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 203

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading

Top 5 Most Recently Viewed Articles

dbt Labs Transforms Data Management with MetricFlow Open Source

Updated Category News Views 735

Embracing Open Source with MetricFlow In a groundbreaking move, dbt Labs recently announced its commitment to advancing trustworthy AI by open sourcing MetricFlow. This initiative represents a significant turning point in how organizations manage and utilize data in the era of artificial intelligence. The shift to an Apache 2.0 license not only safeguards the integrity of...

Continue Reading
EssilorLuxottica Achieves Euro 2 Billion Bond Issuance Success

Updated Category News Views 117

EssilorLuxottica's Successful Bond Issuance EssilorLuxottica has reached a noteworthy milestone by successfully issuing a Euro 2 billion bond at an attractive average rate of 2.99%. This strategic financial move highlights the company's strong position in the market and its appeal to investors. Details of the Bond Issuance The bond issuance features tenors of 4.5 years...

Continue Reading
Streamlined Home Selling Solutions Introduced in North Carolina

Updated Category News Views 292

Revolutionizing Home Selling in North Carolina Fair Cash Offers For Homes has recently launched its innovative service, ‘Sell Your House Fast North Carolina,’ designed to facilitate quick and efficient sales for homeowners. With the ever-changing real estate landscape, many individuals find themselves needing to sell their properties under various circumstances,...

Continue Reading
Ipsen Employee Admits to Insider Trading on Cancer Drug Deal

Updated Category News Views 268

Guilty Plea Tied to a Drugmaker’s Takeover Plans An employee at the French pharmaceutical company Ipsen has agreed to plead guilty to insider trading. The case, centered on trading ahead of a proposed acquisition, underscores the stakes around confidentiality in drug development and the pressures that test corporate governance. What Prosecutors Allege Dishant Gupta,...

Continue Reading
Oscar Health Achieves 52-Week Record with $23.45 Stock Price

Updated Category News Views 221

Oscar Health Achieves New Stock Performance Highs In a striking example of market resilience, Oscar Health, Inc. (OSCR) has reached an impressive 52-week high with its stock hitting $23.45. This achievement signifies a remarkable growth phase for the company, which has experienced an incredible one-year change of 288.51%. Investors have shown strong support for Oscar...

Continue Reading